SpringWorks Therapeutics — Investor Day (June 2022)
87 slides from SpringWorks Therapeutics's investor day presentation, Jun 10, 2022
Slide 1: SpringWorks R&D Day
June 10, 2022 SpringWorks R&D Day
Slide 2: Forward-looking statements note
2 Note: Unless otherwise indicated, the information presented herein is as of June 2022 and made publicly available on June 10, 20 22. This presentation may contain “forward - looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, relating to our
Slide 3: SpringWorks Participants
3 SpringWorks Participants Saqib Islam Chief Executive Officer Badreddin Edris, PhD Chief Operating Officer SpringWorks Leadership Team and External Speakers Participating Today L. Mary Smith, PhD Chief Development Officer Bhavesh Ashar Chief Commercial Officer Mike Burgess, MBChB, PhD Head of R&D E
Slide 4: Agenda
4 Agenda Program Session Presenter Introduction and Business Overview Saqib Islam Badreddin Edris, PhD Nirogacestat KOL Presentation: Unmet Need in Desmoid Tumors Bree Wilky, MD (CU Denver) Clinical Experience in Desmoid Tumors Mary Smith, PhD Desmoid Tumor Commercial Opportunity Bhavesh Ashar Addit
Slide 5: Introduction
Introduction Saqib Islam, Chief Executive Officer Badreddin Edris, PhD, Chief Operating Officer
Slide 6: The full potential of targeted oncology is waiting to be unlocked
6 THE FULL POTENTIAL OF TARGETED ONCOLOGY IS WAITING TO BE UNLOCKED. 2022 2 $381M SpringWorks ’ Efforts Over the Past 5 Years Have Led To… First NDA filing on track for later this year Marketed products by 2025 with potential to serve patients across 4 indications Runway into 2024 (1) …with the sing
Slide 7: Executive Leadership Team
7 Executive Leadership Team: Demonstrated Track Record of Advancing and Commercializing Transformative Oncology Therapies Saqib Islam Chief Executive Officer Badreddin Edris, PhD Chief Operating Officer Mike Burgess, MBChB, PhD Head of R&D Jim Cassidy, MD, PhD Chief Medical Officer Bhavesh Ashar Chi
Slide 8: Repeatable and Sustainable Business Model
8 EXPAND 3 DELIVER 4 DEVELOP 2 IDENTIFY 1 ▪ Partner of choice for leading academic and industry asset originators ▪ Versatile and validated molecules with pipeline - in - a - product potential ▪ Fit - for - purpose business development ▪ Patient - centric clinical development ▪ Translational insight
Slide 9: Unlocking the Full Potential of Every Molecule
9 Unlocking the Full Potential of Every Molecule Note: * Being developed as a combination therapy. Nirogacestat (Gamma secretase inhibitor) Multiple Myeloma* Desmoid Tumors Mirdametinib (MEK inhibitor) NF1 Plexiform Neurofibromas Pediatric Low - Grade Glioma RAS/RAF Mutant Solid Tumors* ER
Slide 10: Pipeline by compound and indication
10 Note: Nirogacestat = PF - 03084014 and Mirdametinib = PD - 0325901 (both in - licensed from Pfizer). * Received Orphan Drug, Fast Track and Breakthrough Therapy Designations. † Received Orphan Drug and Fast Track Designations. (1) Being developed by MapKure , LLC, jointly owned by SpringWorks and
Slide 11: On the Path to Multiple Revenue Generating Opportunities by 2025
11 On the Path to Multiple Revenue Generating Opportunities by 2025 2022 2019 2025 Plan ▪ First patients dosed in DeFi and ReNeu trials ▪ First BCMA collaboration signed with GSK ▪ 5 total programs in development ▪ Nasdaq IPO ▪ Positive topline results from DeFi trial in desmoid tumors ▪ First NDA s
Slide 12: Clinical data and strategic priorities
12 Clinical Data Across Our Three Oncology Segments Nirogacestat: ▪ Phase 3 DeFi topline results in desmoid tumors Nirogacestat + BCMA therapies: ▪ Initial clinical data from combo trial with GSK (low - dose BLENREP) Biomarker - defined solid tumors: ▪ Phase 1b/2 initial data readout from MEK/RAF
Slide 13: Nirogacestat
Nirogacestat 2¢ SpringWorks
Slide 14: Nirogacestat overview
14 (1) Orphan Drug, Fast Track and Breakthrough Therapy Designations received from FDA for desmoid tumors and Orphan Drug Design ati on received from European Commission for soft tissue sarcoma. Clinical Trials Ongoing or On Track for 2022 Initiation: BCMA Collaborations: US Composition of Matter an
Slide 15: Nirogacestat: Clinical Experience in Desmoid Tumors
Nirogacestat: Clinical Experience in Desmoid Tumors 2 SpringWorks L. Mary Smith, PhD, Chief Development Officer THERAPEUTICS
Slide 16: Nirogacestat: Clinical Experience in Desmoid Tumors
Nirogacestat: Clinical Experience in Desmoid Tumors L. Mary Smith, PhD, Chief Development Officer
Slide 17: Encouraging Phase 2 Data in Progressing Desmoid Tumors
17 Encouraging Phase 2 Data in Progressing Desmoid Tumors Demonstrated at the Time of 2017 Publication Note: Per RECIST 16/17 patients were evaluable. One treatment cycle = 150 mg BID continuously for 21 days. Patient #1 had a m iss ing baseline measurement (but had MRI). Patient #14 was not evaluab
Slide 18: 2022 Data Cut Demonstrated 4.4 Years Median Time on Treatment
18 With Maturation of Trial, 2022 Data Cut Demonstrated 4.4 Years of Median Time on Treatment Source: O’Sullivan Coyne et al., ASCO , 2022. PHASE 3 PHASE 1 PHASE 2 Long - Term Progression Free Survival ▪ Among 17 treated patients, median time on treatment 4.4 years (range: 0.17 – 7.99 years) ▪ 4 pat
Slide 19: Phase 3 DeFi Trial Design
19 Phase 3 DeFi Trial Was Designed to Robustly Demonstrate Clinical Benefit of Nirogacestat (1) A total of 51 events will provide 90% power and a 1 - sided type 1 error rate of 0.025 (1 - side hypothesis) to detect a difference between nirogacestat and placebo, assuming the median PFS is 20 months i
Slide 20: Nirogacestat Achieved Primary and All Key Secondary Endpoints in DeFi
20 ▪ Results demonstrated a statistically significant improvement for nirogacestat over placebo, with a 71% reduction in risk of d ise ase progression as assed by blinded independent central review (hazard ratio (HR) = 0.29; P < 0.001) ▪ Statistical significance was achieved on all key secondary end
Slide 21: Putting Ovarian Dysfunction Into Context
21 ▪ Other therapeutic options for the treatment of desmoid tumors have the potential to impact ovarian function and/or embryo - fetal health, including: – Chemotherapy – Tyrosine kinase inhibitors – Radiation Putting Ovarian Dysfunction Into Context Note: MedDRA = Medical Dictionary for Regulatory
Slide 22: Next Steps for the DeFi Program
22 Next Steps for the DeFi Program Detailed study results expected to be presented at a medical conference and published in a peer - reviewed journal in 2H 2022 FDA NDA filing is projected for 2H 2022 ▪ Nirogacestat currently has Orphan Drug, Fast Track, and Breakthrough Therapy Designations ▪ FDA a
Slide 23: Nirogacestat: Desmoid Tumor Commercial Opportunity
Nirogacestat: Desmoid Tumor Commercial Opportunity Bhavesh Ashar, Chief Commercial Officer
Slide 24: We Are Eager to Serve the Desmoid Tumor Community
24 We Are Eager to Serve the Desmoid Tumor Community
Slide 25: Real-World Perspectives Highlight the Significant Unmet Need
25 Real - World Perspectives Highlight the Significant Unmet Need Source: SWTX Qualitative Research with HCPs and patients. " I have done 3 amputations in the last 2 years. I would argue that these are not benign tumors!” – Surgical oncologist (sarcoma specialist) “This tumor is aggressive. I have s
Slide 26: Building Blocks to Support a Substantial Market Opportunity
26 Building Blocks to Support a Substantial Market Opportunity Potential to be first and best in category 0HGLFDO2QFRORJLVWV 6XUJHRQV RISK\VLFLDQV &RPSDUHVIDYRUDEO\ &RPSDUHVVLPLODUO\ &RPSDUHVXQIDYRUDEO\ 1LURJDFHVWDW&RPSDUHGWR6RUDIHQLE S
Slide 27: Desmoid Tumor Physician Treatment Goals
27 DeFi endpoints are well aligned to the most important desmoid tumor treatment goals 60% 59% 51% 49% 48% 48% 47% 38% 34% 34% 32% 0% 10% 20% 30% 40% 50% 60% 70% Improvement in quality of life Durable response to treatment Avoiding severe outcomes of disease progression Durable stabilization of dise
Slide 28: Existing Off-label Systemic Therapy Options Have Significant Limitations
28 Therapy FDA Approval Status for DT Phase 3 Evidence Statistically Significant Improvement in PFS (Primary Endpoint) Statistically Significant Improvement in ORR (Secondary Endpoint) Statistically Significant Improvement in PROs/QoL (Secondary Endpoint) Female Reproductive Toxicity considerations
Slide 29: Female Reproductive Toxicity Concerns and Treatment Decisions
29 5RXQGHG$YHUDJH 7., &KHPRWKHUDSHXWLFDJHQWV 6XUJHU\ )UHTXHQWO\ 2FFDVLRQDOO\ ,QIUHTXHQWO\ 1RWXVHG )UHTXHQF\ZLWK:KLFK3K\VLFLDQV&XUUHQWO\ 'LVFXVV7UHDWPHQW 5HODWHG)HUWLOLW\&RQFHUQV Female Reproductive Toxicity Concerns Are Expected to Impact Treatment Decisions for a Minor
Slide 30: Launch Activities Rapidly Advancing
30 Launch Activities Rapidly Advancing to Ensure Successful Preparation of Market, Organization and Brand Preparing the Market Preparing the Brand Preparing the Organization Establishing deep understanding of the unmet needs and identifying opportunities to generate awareness, educate, and improve t
Slide 31: Summary of the Desmoid Tumor Opportunity
31 Summary of the Desmoid Tumor Opportunity ~ 1,000 – 1,650 incident/new cases, and large prevalent pool with ~5,500 – 7,000 patients actively receiving treatment annually in the U.S. Nirogacestat differentiated based on evidence of efficacy , manageable tolerability , QoL improvement and oral conve
Slide 32: Nirogacestat: Additional Expansion Opportunity
Nirogacestat : Additional Expansion Opportunity Badreddin Edris, PhD, Chief Operating Officer
Slide 33: Nirogacestat in Ovarian Granulosa Cell Tumors
Nirogacestat in Ovarian Granulosa Cell Tumors: Monotherapy Expansion Opportunity in Rare Ovarian Cancer with Significant Unmet Need 33 ▪ No currently approved therapies and limited treatment options ▪ Surgery is mainstay of treatment, but ~40% of patients experience recurrence ▪ Systemic therapies (
Slide 34: Gamma Secretase Inhibitors Could Address Need in OvGCT
34 Gamma Secretase Inhibitors Could Address Need for Targeted Therapy Options in OvGCT OvGCT are potentially susceptible to gamma secretase inhibition due to mutations in FOXL2 Threshold for inclusion in NCCN guidelines likely to be low given precedents and limited therapeutic options ▪ Modest activ
Slide 35: OvGCT physician market research survey
35 ▪ Preliminary market research survey conducted to assess practice demographics and current treatment practices and to gather feedback on physician need for new treatments for OvGCT – Responses were collected from 31 physicians, including OB - GYNs, gynecologic oncologists, gynecologic surgeons an
Slide 36: Phase 2 Study in Recurrent OvGCT
36 Phase 2 Study of Nirogacestat in Recurrent Ovarian Granulosa Cell Tumors Note: BID: twice daily; IND: investigational new drug. PHASE 2 Trial Summary ▪ Single - arm open label study to determine the efficacy, tolerability, safety, and pharmacokinetics of nirogacestat for the treatment of recurren
Slide 37: Nirogacestat: BCMA Combination Therapy Development
Nirogacestat: BCMA Combination Therapy Development Mike Burgess, MBChB, PhD, Head of Research and Development
Slide 38: Nirogacestat in Multiple Myeloma: Combination Backbone for BCMA Therapies
Nirogacestat in Multiple Myeloma: A Potentially Best - in - Class Combination Backbone for BCMA - Directed Therapies 38 Nirogacestat is positioned to be a potential cornerstone of BCMA combination therapy ▪ Combination use being investigated across all BCMA - targeted therapy modalities ▪ Potential
Slide 39: Multiple myeloma oncology revenue opportunity
39 ▪ Multiple myeloma represents the 3rd largest oncology revenue opportunity despite having a lower 5 - year prevalence than solid tumors including breast, prostate, lung, and colorectal – Opportunity driven by long durations of therapy, particularly in early lines – First - and second - line drug
Slide 40: Eight Clinical Collaborations Covering All Key BCMA Modalities
40 Eight Clinical Collaborations Ongoing Covering All Key BCMA Therapeutic Modalities Collaborator Program Modality Collaboration Signed Current Status ADC Bispecific CAR - T mAb BLENREP (belantamab mafodotin) x June 2019 Advanced into randomized Phase 2 trial ALLO - 715 x January 2020 Phase 1 trial
Slide 41: Leading Mechanistic Understanding of GSI + BCMA
41 SpringWorks is Leading the Mechanistic Understanding and Clinical Development of GSI + BCMA in Multiple Myeloma Note: GSI: gamma secretase inhibitor.
Slide 42: Nirogacestat Validated Preclinically with BCMA Therapies
42 Nirogacestat Has Been Validated Preclinically in Combination with BCMA Therapies Across All Key Modalities Sources: (1) Eastman et al., ASH , 2019; (2) Karwacz et al., AACR , 2020; (3) Balakumaran , A. et al., “Combination therapies of chimeric antigen receptors targeting B - cell maturation anti
Slide 43: Gamma Secretase Inhibition Increases Membrane BCMA
43 Gamma Secretase Inhibition Shown to Increase Membrane BCMA in Multiple Myeloma Patients Source: Cowan et al., ASH , 2019. Note: GSI (gamma secretase inhibitor ) data shown from crenigacestat . Median BCMA Expression Post GSI is 99% (96 - 100%) Median 20 - Fold Increase in BCMA Surface Density (8
Slide 44: GSI Consistently Increases BCMA Receptor Density
44 With Longer Follow - up and More Patients, GSI Demonstrated Consistent Ability to Increase BCMA Receptor Density Source: Cowan et al., ASH , 2021. Note: GSI (gamma secretase inhibitor ) data shown from crenigacestat . BCMA Ab Binding Capacity (ABC) Patient GSI (JSMD194/ Crenigacestat ) treatment
Slide 45: Nirogacestat Expands BCMA CAR-T Cells in Patients
45 Preliminary Clinical Data Demonstrate That Nirogacestat Treatment Can Lead to Profound Expansion of BCMA CAR - T Cells in Relapsed/Refractory Multiple Myeloma Patients Note: DL: dose level. Source: Precision BioSciences investor materials (presented 12/11/21); preliminary data from ongoing Precis
Slide 46: BLENREP Approval and Keratopathy Rationale
46 ▪ BLENREP RRMM approval study (DREAMM - 2) utilized 2.5 mg/kg Q3W monotherapy dose and schedule, resulting in deep and durable responses in a triple - class refractory population with a 31% ORR (1) ▪ In DREAMM - 2, a 44.5% Grade 3/4 keratopathy rate using KVA scale was observed – keratopathy lead
Slide 47: Low-dose BLENREP + Nirogacestat Advanced to Randomized Phase 2
47 Initial Low - dose BLENREP + Nirogacestat DREAMM - 5 Cohort Has Advanced to Randomized Phase 2 Expansion Cohort Note: SoC = standard of care. Additional sub - studies with standard - of - care agents expected to commence dosing mid - year Combination (n = 35 ) 0.95 mg/kg BLENREP Q3W + 100 mg BID
Slide 48: Interim DREAMM-5 Data Presented at ASCO 2022
48 Interim Data from DREAMM - 5 Study Evaluating Nirogacestat in Combination with Low - dose BLENREP vs. BLENREP Monotherapy Presented at ASCO 2022 Note: CE: Cohort Expansion; DE: Dose Exploration; BID: twice daily. Source: Lonial et al., ASCO , 2022. Patient Characteristics 2.5 mg/kg BLENREP CE (N
Slide 49: Non-Ocular Adverse Events at Interim Analysis
49 No Significant Difference Noted in Grade ≥ 3 Non - Ocular AEs Between Combination and BLENREP Monotherapy at Interim Analysis Note: Five patient deaths were also reported on study, all unrelated to study treatment. Source: Lonial et al., ASCO , 2022. Drug - Related Grade ≥3 Adverse Events by Syst
Slide 50: Reduction in Ocular Adverse Events with Combination
50 Reduction in Ocular Adverse Events Observed with Combination Versus BLENREP Monotherapy at Interim Analysis Note: CE: Cohort Expansion; DE: Dose Exploration; BID: twice daily; CTCAE: common terminology criteria for adverse events; KV A: keratopathy and visual acuity. Note: BLENREP + niro combinat
Slide 51: Emerging Efficacy Profile of Low-dose BLENREP + Nirogacestat
51 Emerging Efficacy Profile of Low - dose BLENREP in Combination with Nirogacestat Note: PR: partial response; VGPR: very good partial response; BID: twice daily; CE: cohort expansion, DE: dose exploration; Q 3W: once every 3 weeks. Source: Lonial et al., ASCO , 2022. 21% 17% CE: 2.5mg/kg Q3W Blenr
Slide 52: Nirogacestat May Help Open Path for BLENREP in Earlier Lines
52 Nirogacestat May Help Open the Path for BLENREP in Earlier Treatment Lines Note: MRD: minimal residual disease; NDMM: newly diagnosed multiple myeloma; ORR: objective response rate; PFS: progression - free survival; POC: proof of concept; RRMM: relapsed/refractory multiple myeloma; SoC: standard
Slide 53: Additional Data Readouts and Trial Starts Anticipated in 2022
53 ▪ DREAMM - 5 Randomized Cohort Expansion (Phase 2): Updated data on additional patients with longer follow - up expected in 2H22 ▪ DREAMM - 5 Sub - studies: Enrollment to be initiated mid - year in cohorts combining low - dose BLENREP and nirogacestat with lenalidomide/dexamethasone and with poma
Slide 54: Mirdametinib
Mirdametinib 2 SpringWorks
Slide 55: Mirdametinib: Potent and Selective MEK Inhibitor
Mirdametinib: Potent and Selective MEK Inhibitor With Differentiated Safety Profile Mirdametinib is an investigational oral, allosteric MEK1/2 inhibitor with over 10 years of clinical experience Granted Orphan Drug Designation for NF1 by FDA and European Commission and Fast Track Designation for NF1
Slide 56: Mirdametinib overview
56 Note: NF1 - PN: Neurofibromatosis type 1 - associated plexiform neurofibroma; DDI: drug - drug interaction. Pediatric and Adult NF1 - PN Patients Enrolled on ReNeu Clinical Trials Ongoing or On Track for 2022 Initiation: US Composition of Matter Patent Protection: ▪ Mirdametinib is an investigati
Slide 57: Biomarker-Guided Pipeline-in-a-Molecule Strategy for Mirdametinib
57 Biomarker - Guided Pipeline - in - a - Molecule Development Strategy for Mirdametinib Sources: (1) Estimates are rounded and based on incidence reported by American Cancer Society Cancer Facts & Figures 2021 (US ) a nd other sources as noted. (2) Rasmussen et al., Am J Epidemiol ., 2000; Ferner e
Slide 58: Mirdametinib: NF1-PN
Mirdametinib: NF1 - PN L. Mary Smith, PhD, Chief Development Officer
Slide 59: Plexiform Neurofibromas Are Painful, Disfiguring Tumors
59 Plexiform Neurofibromas Are Painful, Disfiguring Tumors That Grow Along Peripheral Nerve Sheaths 59 Kendall NF1 Patient ▪ MEK inhibitors are a validated class for NF1 - PN treatment ▪ Surgical resection is challenging due to the infiltrative tumor growth pattern along nerves and can lead to perma
Slide 60: ReNeu Trial Summary
60 Note: BID: twice daily; PN: plexiform neurofibroma. Trial Summary ▪ Study fully enrolled with 114 patients in 2 cohorts (pediatric, adult participants) across ~50 sites in the US ▪ 2 mg/m 2 BID dosing with intermittent course (4 - week cycles of 3 weeks on, 1 week off) for up to 24 cycles – Maxim
Slide 61: Mirdametinib NF1-PN Program Highlights
61 ▪ Mirdametinib has the potential to benefit a broader set of NF1 - PN patients – MEK inhibitors are a proven therapeutic approach for NF1 - PN – NF1 - PN is rapidly emerging as a validated commercial market – No currently approved treatment for the adult NF1 - PN population – Potential for approv
Slide 62: Mirdametinib: Additional Expansion Opportunities
Mirdametinib: Additional Expansion Opportunities Jim Cassidy, MD, PhD, Chief Medical Officer
Slide 63: Phase 1/2 Trial in Pediatric Low-Grade Glioma
63 Phase 2 Trial in Pediatric Low - Grade Glioma Provides Additional Expansion Opportunity for Mirdametinib Note: BID: twice daily; ISPNO: International Symposium on Pediatric Neuro - Oncology; LGG: low - grade glioma; RP2D: recommended Pha se 2 dose. Summary of Endpoints ▪ Primary Endpoint: Objecti
Slide 64: MEK Inhibitors Can Address Endocrine Therapy Resistance in ER+ Breast Cancer
64 Mirdametinib : MEK Inhibitors Can Potentially Address Endocrine Therapy Resistance Due to MAPK Mutations in ER+ Breast Cancer Note: B: buparlisib (PI3K inhibitor); BC: breast cancer; F: fulvestrant ; LoF : loss of function; mBC : metastatic breast cancer; S: selumetinib (MEK inhibitor); SoC: stan
Slide 65: Activity in Preclinical Models Driven by MEK1/2 Mutations
65 Mirdametinib: Activity Demonstrated in Preclinical Models Driven by Activating Mutations in MEK1 and MEK2 Source: Gao et al., Cancer Discovery, 2018; Hanrahan et al., Cancer Research, 2020. ▪ Mirdametinib shows potent preclinical activity against Class 1 and Class 2 mutations in MEK1 and MEK2 ▪ M
Slide 66: MAPK Targeted Portfolio with BeiGene Collaborations
66 Building on Mirdametinib’s Potential Best - In - Class Profile, We Developed Our MAPK Targeted Portfolio with Complementary Combination Opportunities in Collaboration with BeiGene Demonstrated activity and tolerability of vertical MAPK pathway inhibition in RAS and RAF mutant solid tumors with mi
Slide 67: Mirdametinib + Lifirafenib Preclinical Synergy
67 Mirdametinib + Lifirafenib : Combination Synergy Demonstrated Across RAS Mutant Preclinical Models Informed Phase 1 Study Design Sources: Desai et al., J Clin Oncol , 2020; Tang et al., Mol Cancer Ther , 2015; Yuan et al., Molecular Oncology , 2020; Yuan et al., AACR, 2020. Preclinical synergy de
Slide 68: Patients Enrolled in Dose Escalation Cohort
68 Diverse Group of Solid Tumor Patients with MAPK Activating Mutations Enrolled in Dose Escalation Cohort of the Mirdametinib and Lifirafenib Study As of 11/05/21 Note: Data are preliminary, investigator assessed, and have not been centrally reviewed; response data as of 11/05/21. Baseline Characte
Slide 69: Clinical Efficacy Observed During Dose Escalation
69 Mirdametinib + Lifirafenib: Clinical Efficacy Observed During Dose Escalation As of 11/05/21 CR: complete response; CRC: colorectal cancer; HGSOC: high - grade serous ovarian carcinoma; LGSOC: low - grade serous ovarian carci noma; MPNST: malignant peripheral nerve sheath tumor; PD: progressive d
Slide 70: LGSOC Patients Demonstrate Potential for Long Term Responses
70 ▪ 100% Disease Control Rate (DCR) with median time on therapy of ~26 months with 10 of 11 patients remaining on therapy (13 - 34 mon ths) as of May 2022 ▪ 73% ORR in LGSOC (1 CR + 7 PRs (out of 11), 3 durable SDs ≥72 weeks) with deepening or stable responses over time ▪ Responses seen irrespectiv
Slide 71: Patient Vignette: KRAS G12D-mutant LGSOC
71 ▪ Patient initiated therapy in September 2020 and achieved a 77% reduction from baseline at Week 48 (time of first response: Week 8) by RECIST v1.1 with continued stability in tumor size and CA - 125 levels – 62 - year - old female with low grade serous ovarian carcinoma – 3 lines of prior treatm
Slide 72: Acceptable Safety and Tolerability Profile
72 All - cause adverse event profile aligns with relapsed/refractory cancer patients generally; related TEAEs have been manageable with few treatment discontinuation due to adverse events; expected publication at a future medical conference Evidence of Acceptable Safety and Tolerability Profile with
Slide 73: Joint Venture with BeiGene to Advance BGB-3245
73 Joint Venture with BeiGene Created to Advance BGB - 3245 Through Clinical Development ▪ BGB - 3245 is an investigational next - generation oral, selective small molecule RAF dimer inhibitor ▪ BGB - 3245 has demonstrated 5 - 10x greater potency than lifirafenib in inhibiting RAF - dimer activity i
Slide 74: BGB-3245: Clinical Data Update
BGB - 3245: Clinical Data Update Jim Cassidy, MD, PhD, Chief Medical Officer
Slide 75: BGB-3245 Phase 1a/1b Study Design
75 BGB - 3245 Monotherapy Phase 1a/1b Study Design Note: RP2D: recommended Phase 2 dose. Solid tumors with BRAF non - V600 mutations BRAF V600 melanoma progressed on prior BRAF/ MEKi Phase 1a Advanced solid tumors with BRAF or RAS mutations NRAS Mutant Melanoma Safety follow - up Phase 1b BGB - 3245
Slide 76: BGB-3245 Patient Characteristics in Dose Escalation
76 BGB - 3245 Monotherapy Patient Characteristics in Dose Escalation As of 02/26/22 Note: Data are preliminary, investigator assessed, and have not been centrally reviewed. Enrollment as of 02/26/22. Baseline Characteristics Overall, n (%) Patients treated Still on Treatment 38 (100) 14 (36.8) Sex M
Slide 77: Early Clinical Efficacy Observed in Dose Escalation
77 BGB - 3245: Early Clinical Efficacy Observed in Dose Escalation As of 02/26/22 Note: CRC: colorectal cancer; IO: immuno - oncology; LMS: leiomyosarcoma; LGSOC: low - grade serous ovarian cancer; NSCLC: non - small cell lung cancer; PD: progressive disease; PR: partial response; SD: stable disease
Slide 78: Rapid Objective Responses in BRAF V600 Melanoma
78 Emerging Clinical Data Highlight Rapid Objective Responses in Metastatic BRAF V600 Melanoma Patients Progressed on Existing I - O and MEK + BRAF Treatments As of 02/26/22 ▪ 39 - year - old man presented with BRAF V600E - mutated melanoma and had previously received 2 prior lines of treatment, inc
Slide 79: BGB-3245 Emerging Safety Profile
79 BGB - 3245 Emerging Safety Profile Manageable and Consistent with MAPK Pathway Inhibitors As of 01/10/22 Note: TEAE: treatment - emergent adverse event. Note: Data are preliminary, investigator assessed, and have not been centrally reviewed. Safety data as of 01/10/22. Grade ≥3 TEAE – All Cause M
Slide 80: Future Development for BeiGene Collaborations Portfolio
80 Mirdametinib + Lifirafenib ▪ Complete Phase 1 dose finding 2H 2022 prior to expansion studies ▪ Data from ongoing study expected to be presented at a medical conference in 2H 2022 BGB - 3245 ▪ Complete dose escalation and determine RP2D in 2H 2022 ▪ Data from ongoing study expected to be presente
Slide 81: Preclinical Pipeline
Preclinical Pipeline Mike Burgess, MBChB, PhD, Head of Research and Development
Slide 82: TEAD Inhibitor Program in Lead Optimization
82 -10 -9 -8 -7 -6 -5 0 50 100 -10 -9 -8 -7 -6 -5 0 50 100 TEAD inhibitors potently and selectively inhibit growth of cancer cell lines driven by Hippo pathway mutations 1 Compounds have shown good tolerability and oral bioavailability in vivo, with dose dependent tumor growth inhibition in Hippo al
Slide 83: EGFR Inhibitor Portfolio
83 EGFR Inhibitor Portfolio: Developing Several Novel Targeting Approaches to Address De Novo Oncogenic Drivers and Resistance Mechanisms ▪ EGFR inhibition is a validated therapeutic approach – limitations of existing agents center on development of resistance and subgroups with suboptimal responses
Slide 84: The SpringWorks Opportunity
The SpringWorks Opportunity
Slide 85: Foundation in Place to Drive Sustainable Growth in 2022+
Foundation in Place to Drive Sustainable Growth and Value Creation in 2022+ ▪ Executing late - stage development programs for nirogacestat and mirdametinib, with positive DeFi readout expected to yield first FDA - approved therapy for DT patients ▪ Advancing nirogacestat as a cornerstone of BCMA com
Slide 86: Value-Driving Data Readouts Anticipated in 2022
Value - Driving Data Readouts and Program Updates Anticipated Across the Pipeline in 2022 86 Note: ISPNO: International Symposium on Pediatric Neuro - Oncology; RRMM = relapsed/refractory multiple myeloma; LGG = low - grade g lioma. Milestone Expected Timing Nirogacestat Phase 3 DeFi topline readout
Slide 87: Q&A Instructions and Participants
87 Instructions ▪ Call the appropriate participant dial - in number ▪ Provide the operator with the conference ID Dial - in numbers ▪ US: (844) 946 - 0285 ▪ International: (602) 585 - 9676 Conference ID ▪ 4453188 Helpful keypad commands ▪ *0 - Operator assistance ▪ *6 - Self mute/unmute Q&A Particip